Research Companies

Curavac/Myasterix

myasterix

The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for myastenia gravis (MG) to clinical proof of concept studies.

Curavac

curavac 012

CuraVac is an innovative company founded to take a newly discovered technique for creating therapeutic vaccines against autoimmune diseases from discovery through to being available for treatment of humans. CuraVac is an innovative company founded to take a newly discovered technique for creating therapeutic vaccines against autoimmune diseases from discovery through to being available for treatment of humans.

Typical autoimmune diseases that should be treatable by CuraVac vaccines include myasthenia gravis, multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosis.

The first in human trial of the MG therapeutic vaccine will begin in Europe during the first quarter of 2015.

Alexion Pharmaceuticals

Alexion

Alexion is currently focused on clinical programs in four such disorders, acute humoral transplant rejection STEC-HUS, neuromyelitis optica and myasthenia gravis. And we will drive these programs forward throughout 2012.

Finally with eculizumab, we have two neurology clinical development programs ongoing in severe and refractory neuromyelitis optica and in myasthenia gravis. Data from the investigator initiated space to clinical trail of eculizumab in severe refectory NMO is expected later this year.

With regard to myasthenia gravis, data from our company sponsored Phase II study was presented in the fall of 2011. The data showed a strong disease improvement signal in a group of 14 patients with severe and refractory myasthenia gravis, an ultra-rare debilitating form of the disease. We expect to discuss the plans for a larger prospective placebo controlled study with regulators in 2012.

Alexion is studying Soliris for additional indications as well, such as acute humoral rejection, myasthenia gravis and STEC-HUS. Currently, there are no approved treatments for any of these disorders and the successful development of Soliris for one or more of these indications will further expand the market potential of the drug.